Display options
Cite
Kash N, Lee MA, Kollipara R, et al. Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. J Clin Med. 2015;4(4):614-33doi: 10.3390/jcm4040614.
Kash, N., Lee, M. A., Kollipara, R., Downing, C., Guidry, J., & Tyring, S. K. (2015). Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. Journal of clinical medicine, 4(4), 614-33. https://doi.org/10.3390/jcm4040614
Kash, Natalie, et al. "Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus." Journal of clinical medicine vol. 4,4 (2015): 614-33. doi: https://doi.org/10.3390/jcm4040614
Kash N, Lee MA, Kollipara R, Downing C, Guidry J, Tyring SK. Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. J Clin Med. 2015 Apr 03;4(4):614-33. doi: 10.3390/jcm4040614. PMID: 26239350; PMCID: PMC4470159.
Copy Download .nbib Format: NLM
Share it on

J Clin Med. 2015 Apr 03;4(4):614-33. doi: 10.3390/jcm4040614.

Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus.

Journal of clinical medicine

Natalie Kash, Michael A Lee, Ramya Kollipara, Christopher Downing, Jacqueline Guidry, Stephen K Tyring

Affiliations

  1. University of Texas Medical School at Houston, Houston, TX 77030, USA. [email protected].
  2. Center for Clinical Studies, Houston, TX 77004, USA. [email protected].
  3. Center for Clinical Studies, Houston, TX 77004, USA. [email protected].
  4. Center for Clinical Studies, Houston, TX 77004, USA. [email protected].
  5. Center for Clinical Studies, Houston, TX 77004, USA. [email protected].
  6. Center for Clinical Studies, Houston, TX 77004, USA. [email protected].
  7. Department of Dermatology, University of Texas Health Science Center at Houston, Houston, TX 77030, USA. [email protected].

PMID: 26239350 PMCID: PMC4470159 DOI: 10.3390/jcm4040614

Abstract

Since the discovery of the causal association between human papillomavirus (HPV) and cervical cancer, efforts to develop an effective prophylactic vaccine to prevent high-risk HPV infections have been at the forefront of modern medical research. HPV causes 530,000 cervical cancer cases worldwide, which is the second most common cause of cancer deaths in women; a worldwide collaboration among epidemiologists, molecular biologists, vaccinologists, virologists, and clinicians helped lead to the development of two highly effective prophylactive HPV vaccines. The first, Gardasil, is a quadrivalent vaccine made up of recombinant HPV L1 capsid proteins from the two high-risk HPV types (16/18) responsible for 70% of cervical cancer cases as well as two low-risk HPV types (6/11) which are the causative agent for genital warts. The second, Cervarix, is a bivalent vaccine that was FDA approved three years after Gardasil and is also composed of L1 capsid proteins from HPV types 16/18. This review article focuses on the safety and efficacy data of both FDA-approved vaccines, as well as highlighting a few advances in future HPV vaccines that show promise in becoming additional treatment options for this worldwide disease.

Keywords: Cervarix; Gardasil; HPV; cervical cancer; pap smear; vaccination; virology

References

  1. Lancet. 2013 Sep 7;382(9895):889-99 - PubMed
  2. Lancet. 2007 Jun 2;369(9576):1861-8 - PubMed
  3. Ann Pharmacother. 2006 Jul-Aug;40(7-8):1344-52 - PubMed
  4. Clin Cancer Res. 2007 Jan 1;13(1):341-9 - PubMed
  5. Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11895-9 - PubMed
  6. Hum Mutat. 2003 Mar;21(3):307-12 - PubMed
  7. Nature. 2000 Dec 7;408(6813):740-5 - PubMed
  8. BMJ. 2014 Mar 04;348:g1458 - PubMed
  9. Vaccine. 2006 Mar 30;24 Suppl 1:S16-22 - PubMed
  10. J Virol. 2007 Nov;81(21):11585-92 - PubMed
  11. Pediatrics. 2012 Aug;130(2):e249-56 - PubMed
  12. Lancet. 2011 Jun 18;377(9783):2085-92 - PubMed
  13. N Engl J Med. 2007 May 10;356(19):1928-43 - PubMed
  14. JAMA. 2007 Aug 15;298(7):743-53 - PubMed
  15. Pharmacotherapy. 2011 Mar;31(3):280-97 - PubMed
  16. J Infect Dis. 1997 Apr;175(4):927-31 - PubMed
  17. Vaccine. 2001 Jun 14;19(27):3652-60 - PubMed
  18. Br J Cancer. 2006 Dec 4;95(11):1459-66 - PubMed
  19. Mol Ther. 2009 May;17(5):906-13 - PubMed
  20. Lancet. 2009 Dec 12;374(9706):1975-85 - PubMed
  21. JAMA. 2014 Feb 12;311(6):597-603 - PubMed
  22. Virology. 2000 May 10;270(2):254-7 - PubMed
  23. Vaccine. 2012 Nov 20;30 Suppl 5:F12-23 - PubMed
  24. Pharmacoepidemiol Drug Saf. 2014 May;23(5):456-65 - PubMed
  25. Lancet. 2006 Apr 15;367(9518):1247-55 - PubMed
  26. Infect Agent Cancer. 2012 Sep 05;7(1):24 - PubMed
  27. JAMA. 2007 Feb 28;297(8):813-9 - PubMed
  28. Cancer Res. 2006 Dec 1;66(23):11120-4 - PubMed
  29. J Virol. 2007 Dec;81(24):13927-31 - PubMed
  30. Vaccine. 2009 Feb 11;27(7):1040-9 - PubMed
  31. Mol Ther. 2007 Aug;15(8):1564-70 - PubMed
  32. Prev Med. 2011 Oct;53 Suppl 1:S12-21 - PubMed
  33. Acta Dermatovenerol Alp Pannonica Adriat. 2011 Sep;20(3):145-54 - PubMed
  34. J Infect Dis. 2010 Dec 15;202(12):1789-99 - PubMed
  35. N Engl J Med. 2011 Oct 27;365(17):1576-85 - PubMed
  36. J Infect Dis. 2007 Nov 15;196(10):1438-46 - PubMed
  37. World J Exp Med. 2012 Aug 20;2(4):65-9 - PubMed
  38. Vaccine. 2007 Jun 21;25(26):4931-9 - PubMed
  39. Microbes Infect. 2014 May;16(5):371-8 - PubMed
  40. Vaccine. 2002 Oct 4;20(29-30):3456-64 - PubMed
  41. Vaccine. 2012 Nov 20;30 Suppl 5:F123-38 - PubMed
  42. J Immunol. 2009 Nov 15;183(10):6151-6 - PubMed
  43. J Adolesc Health. 2007 Jun;40(6):564-71 - PubMed
  44. Lancet. 2009 Jul 25;374(9686):301-14 - PubMed
  45. Clin Infect Dis. 2007 Sep 1;45(5):609-7 - PubMed
  46. N Engl J Med. 2011 Feb 3;364(5):401-11 - PubMed
  47. Oncogene. 2001 Nov 26;20(54):7888-98 - PubMed
  48. Hum Vaccin. 2009 Oct;5(10):705-19 - PubMed
  49. N Engl J Med. 2007 May 10;356(19):1915-27 - PubMed
  50. Nat Rev Clin Oncol. 2014 Sep;11(9):509-24 - PubMed
  51. J Virol. 2010 Feb;84(3):1214-20 - PubMed
  52. Sci Transl Med. 2012 Oct 10;4(155):155ra138 - PubMed
  53. Lancet Oncol. 2005 May;6(5):271-8 - PubMed
  54. Obstet Gynecol. 2006 Jan;107(1):18-27 - PubMed

Publication Types